Beigene Ltd
HKEX:6160

Watchlist Manager
Beigene Ltd Logo
Beigene Ltd
HKEX:6160
Watchlist
Price: 113.8 HKD -2.65% Market Closed
Market Cap: 155.1B HKD
Have any thoughts about
Beigene Ltd?
Write Note

Gross Margin
Beigene Ltd

84.3%
Current
82%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
84.3%
=
Gross Profit
18.7B
/
Revenue
22.2B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
CN
Beigene Ltd
HKEX:6160
156.9B HKD
84%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
67%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
60%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
86%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
78%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
133.6B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
34.8B EUR
89%
Country CN
Market Cap 156.9B HKD
Gross Margin
84%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 312.7B USD
Gross Margin
67%
Country US
Market Cap 158.3B USD
Gross Margin
60%
Country US
Market Cap 116.2B USD
Gross Margin
86%
Country US
Market Cap 112.4B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 133.6B AUD
Gross Margin
52%
Country US
Market Cap 81.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.8B EUR
Gross Margin
89%
No Stocks Found

Beigene Ltd
Glance View

Market Cap
156.9B HKD
Industry
Biotechnology

Beigene Ltd. has emerged as a formidable player in the global biopharmaceutical landscape, primarily focusing on the discovery and development of innovative medicines to treat cancer. Founded in 2010, the company has quickly established itself with a strong commitment to addressing the significant unmet medical needs in oncology. Headquartered in Beijing, China, Beigene's expansive R&D efforts are complemented by an extensive portfolio of targeted therapies, including BTK inhibitors and PD-1 antibodies, which have garnered attention for their effectiveness in treating various malignancies. What sets Beigene apart is its strategic emphasis on global collaboration, combining scientific expertise with a patient-centric approach to accelerate the development of breakthrough therapies. Investors find Beigene's aggressive growth strategy particularly appealing, as the company not only pursues internal drug development but also engages in partnerships and collaborations to enhance its pipeline and market reach. Recently, Beigene's acquisition of the global rights to several key therapies has bolstered its position in the U.S. market, giving it the resources necessary to compete on a larger scale. With its dual listing on both the Nasdaq and the Hong Kong Stock Exchange, Beigene showcases its ambition and adaptability in a rapidly evolving sector. As the company continues to innovate and expand its footprint, it stands poised to capitalize on the increasing global demand for cancer treatments, making it an intriguing prospect for long-term investors seeking exposure to the dynamic biotech industry.

Intrinsic Value
164.36 HKD
Undervaluation 31%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
84.3%
=
Gross Profit
18.7B
/
Revenue
22.2B
What is the Gross Margin of Beigene Ltd?

Based on Beigene Ltd's most recent financial statements, the company has Gross Margin of 84.3%.